Comparison of Chemotherapy With Chemohormonal Therapy as First-Line Therapy for Metastatic, Hormone-Sensitive Breast Cancer: An Eastern Cooperative Oncology Group Study
2000
PURPOSE: Although hormonal therapy represents standard therapy for metastatic hormone-sensitive disease, many patients receive initial chemotherapy because of the location, bulk, or aggressiveness of their disease. It is uncertain whether simultaneous hormonal therapy provides additional benefit compared with chemotherapy alone. Eastern Cooperative Oncology Group trial E3186 was initiated to explore this question. PATIENTS AND METHODS: Between January 1988 and December 1992, 231 patients with estrogen receptor (ER)–positive or ER-unknown metastatic breast cancer were randomized to receive either chemotherapy (cyclophosphamide, doxorubicin, and fluorouracil [CAF]) or chemohormonal therapy (CAF plus tamoxifen and Halotestin [fluoxymesterone; Pharmacia-Upjohn, Kalamazoo, MI] [CAFTH]) as front-line therapy for metastatic breast cancer. Patients who experienced a complete response to induction therapy either received or did not receive maintenance cyclophosphamide, methotrexate, fluorouracil, prednisone, and T...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
13
References
59
Citations
NaN
KQI